BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, has announced the approval of equity grants for 123 new employees. The grants, approved on September 4, 2024, consist of restricted stock units totaling 359,926 shares of the Company's common stock. The vesting schedule begins with one-fourth of the shares vesting on August 16, 2025, followed by quarterly vesting of one-twelfth of the remaining shares, subject to continued employment. These awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as inducement material for new employees joining the Company.
BridgeBio Pharma (Nasdaq: BBIO), una compagnia biofarmaceutica in fase commerciale focalizzata sulle malattie genetiche, ha annunciato l'approvazione di assegnazioni di azioni per 123 nuovi dipendenti. Le assegnazioni, approvate il 4 settembre 2024, consistono in unità di azioni vincolate per un totale di 359.926 azioni delle azioni ordinarie della Compagnia. Il programma di maturazione inizia con un quarto delle azioni che diventano di proprietà il 16 agosto 2025, seguito da una maturazione trimestrale di un dodicesimo delle restanti azioni, soggette a occupazione continua. Questi premi sono stati conferiti ai sensi del Piano di Induzione per Azioni Ampliato e Ristampato del 2019 di BridgeBio, in conformità alla Regola di Quotazione Nasdaq 5635(c)(4), come incentivo materiale per i nuovi dipendenti che si uniscono alla Compagnia.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica en etapa comercial enfocada en enfermedades genéticas, ha anunciado la aprobación de concesiones de acciones para 123 nuevos empleados. Las concesiones, aprobadas el 4 de septiembre de 2024, consisten en unidades de acciones restringidas por un total de 359.926 acciones de las acciones ordinarias de la Compañía. El cronograma de adquisición comienza con un cuarto de las acciones adquiriéndose el 16 de agosto de 2025, seguido de adquisiciones trimestrales de un duodécimo de las acciones restantes, sujeto a la continuación del empleo. Estos premios se otorgaron bajo el Plan de Inducción de Acciones Modificado y Restablecido de 2019 de BridgeBio, de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4), como material de incentivo para los nuevos empleados que se unan a la Compañía.
BridgeBio Pharma (Nasdaq: BBIO)는 유전 질환에 초점을 맞춘 상업 단계의 생명공학 회사로, 123명의 신규 직원에 대한 주식 보상 승인을 발표했습니다. 이 보상은 2024년 9월 4일에 승인되었으며, 회사의 보통주 359,926주에 해당하는 제한된 주식 단위로 구성됩니다. 주식의 완전 소유는 2025년 8월 16일에 1/4이 발생하고, 그 이후로는 남은 주식의 1/12가 분기별로 발생하며, 계속해서 고용 상태를 유지해야 합니다. 이러한 보상은 BridgeBio의 수정 및 재작성된 2019 유도 주식 계획에 따라 이루어졌으며, Nasdaq 상장 규정 5635(c)(4)에 의거하여 회사에 새로 합류하는 직원들을 위한 유인 자료로 제공됩니다.
BridgeBio Pharma (Nasdaq: BBIO), une entreprise biopharmaceutique en phase commerciale axée sur les maladies génétiques, a annoncé l'approbation de concessions d'actions pour 123 nouveaux employés. Les concessions, approuvées le 4 septembre 2024, consistent en des unités d'actions restreintes totalisant 359.926 actions des actions ordinaires de la société. Le calendrier d'attribution commence par un quart des actions qui deviendront acquises le 16 août 2025, suivi d'une attribution trimestrielle d'un douzième des actions restantes, sous réserve d'une poursuite de l'emploi. Ces récompenses ont été accordées dans le cadre du Plan de Concession d’Actions Modifié et Révisé de BridgeBio de 2019, conformément à la Règle de Cotation Nasdaq 5635(c)(4), en tant que matériel d'incitation pour les nouveaux employés rejoignant la société.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf genetische Erkrankungen konzentriert, hat die Genehmigung von Aktienvergaben für 123 neue Mitarbeiter announced. Die am 4. September 2024 genehmigten Vergaben bestehen aus eingeschränkten Aktieneinheiten, die insgesamt 359.926 Aktien des Stammkapitals des Unternehmens betreffen. Der Vesting-Plan beginnt mit einem Viertel der Aktien, die am 16. August 2025 vested, gefolgt von einer vierteljährlichen Vesting von einem Zwölftel der verbleibenden Aktien, vorausgesetzt, die Anstellung bleibt bestehen. Diese Auszeichnungen wurden im Rahmen des überarbeiteten 2019 Induktionsaktienplans von BridgeBio vergeben, gemäß der Nasdaq-listungsregel 5635(c)(4), als Anreizmaterial für neue Mitarbeiter, die dem Unternehmen beitreten.
- Granted equity to 123 new employees, indicating company growth and talent acquisition
- Implemented a structured vesting schedule to encourage employee retention
- Potential dilution of existing shareholders due to the issuance of 359,926 new shares
PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on September 4, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 123 new employees in restricted stock units for an aggregate of 359,926 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
How many new employees received equity grants from BridgeBio Pharma (BBIO) in September 2024?
What is the total number of shares granted in restricted stock units by BridgeBio Pharma (BBIO)?
When does the vesting period begin for the restricted stock units granted by BridgeBio Pharma (BBIO)?
Under which plan were the equity grants made by BridgeBio Pharma (BBIO)?
